Top

Published in:

01-02-2009 | Review

Tissue engineering in the rheumatic diseases

Authors: Jochen Ringe, Michael Sittinger

Published in: Arthritis Research & Therapy | Issue 1/2009

Abstract

Diseases such as degenerative or rheumatoid arthritis are accompanied by joint destruction. Clinically applied tissue engineering technologies like autologous chondrocyte implantation, matrix-assisted chondrocyte implantation, or in situ recruitment of bone marrow mesenchymal stem cells target the treatment of traumatic defects or of early osteoarthritis. Inflammatory conditions in the joint hamper the application of tissue engineering during chronic joint diseases. Here, most likely, cartilage formation is impaired and engineered neocartilage will be degraded. Based on the observations that mesenchymal stem cells (a) develop into joint tissues and (b) in vitro and in vivo show immunosuppressive and anti-inflammatory qualities indicating a transplant-protecting activity, these cells are prominent candidates for future tissue engineering approaches for the treatment of rheumatic diseases. Tissue engineering also provides highly organized three-dimensional in vitro culture models of human cells and their extracellular matrix for arthritis research.

Available only for authorised users

Simon TM, Jackson DW: Articular cartilage: injury pathways and treatment options. Sports Med Arthrosc. 2006, 14: 146-154. 10.1097/00132585-200609000-00006.CrossRefPubMed

Steadman JR, Ramappa AJ, Maxwell RB, Briggs KK: An arthroscopic treatment regimen for osteoarthritis of the knee. Arthroscopy. 2007, 23: 948-955.CrossRefPubMed

Hollander AP, Dickinson SC, Sims TJ, Brun P, Cortivo R, Kon E, Marcacci M, Zanasi S, Borrione A, De Luca C, Pavesio A, Soranzo C, Abatangelo G: Maturation of tissue engineered cartilage implanted in injured and osteoarthritic human knees. Tissue Eng. 2006, 12: 1787-1798. 10.1089/ten.2006.12.1787.CrossRefPubMed

Ossendorf C, Kaps C, Kreuz PC, Burmester GR, Sittinger M, Erggelet C: Treatment of posttraumatic and focal osteoarthritic cartilage defects of the knee with autologous polymer-based three-dimensional chondrocyte grafts: 2-year clinical results. Arthritis Res Ther. 2007, 9: R41-10.1186/ar2180.PubMedCentralCrossRefPubMed

Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science. 1999, 284: 143-147. 10.1126/science.284.5411.143.CrossRefPubMed

Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU: In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell Res. 1998, 238: 265-272. 10.1006/excr.1997.3858.CrossRefPubMed

Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP: Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J Cell Biochem. 1997, 64: 295-312. 10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I.CrossRefPubMed

Caplan AI, Dennis JE: Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006, 98: 1076-1084. 10.1002/jcb.20886.CrossRefPubMed

Jorgensen C, Djouad F, Bouffi C, Mrugala D, Noël D: Multipotent mesenchymal stromal cells in articular diseases. Best Pract Res Clin Rheumatol. 2008, 22: 269-284. 10.1016/j.berh.2008.01.005.CrossRefPubMed

10.

Fedewa MM, Oegema TR, Schwartz MH, MacLeod A, Lewis JL: Chondrocytes in culture produce a mechanically functional tissue. J Orthop Res. 1998, 16: 227-236. 10.1002/jor.1100160210.CrossRefPubMed

11.

Andreas K, Lübke C, Häupl T, Dehne T, Morawietz L, Ringe J, Kaps C, Sittinger M: Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther. 2008, 10: R9-10.1186/ar2358.PubMedCentralCrossRefPubMed

12.

Ibold Y, Frauenschuh S, Kaps C, Sittinger M, Ringe J, Goetz PM: Development of a high-throughput screening assay based on the 3-dimensional pannus model for rheumatoid arthritis. J Biomol Screen. 2007, 12: 956-965. 10.1177/1087057107307147.CrossRefPubMed

13.

Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L: Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med. 1994, 331: 889-895. 10.1056/NEJM199410063311401.CrossRefPubMed

14.

Micheli LJ, Browne JE, Erggelet C, Fu F, Mandelbaum B, Moseley JB, Zurakowski D: Autologous chondrocyte implantation of the knee: multicenter experience and minimum 3-year follow-up. Clin J Sport Med. 2001, 11: 223-228. 10.1097/00042752-200110000-00003.CrossRefPubMed

15.

Peterson L, Minas T, Brittberg M, Nilsson A, Sjogren-Jansson E, Lindahl A: Two- to 9-year outcome after autologous chondrocyte transplantation of the knee. Clin Orthop Relat Res. 2000, 374: 212-234. 10.1097/00003086-200005000-00020.CrossRefPubMed

16.

Roberts S, McCall IW, Darby AJ, Menage J, Evans H, Harrison PE, Richardson JB: Autologous chondrocyte implantation for cartilage repair: monitoring its success by magnetic resonance imaging and histology. Arthritis Res Ther. 2003, 5: R60-73. 10.1186/ar613.PubMedCentralCrossRefPubMed

17.

Steinwachs M, Kreuz PC: Autologous chondrocyte implantation in chondral defects of the knee with a type I/III collagen membrane: a prospective study with a 3-year follow-up. Arthroscopy. 2007, 23: 381-387.CrossRefPubMed

18.

Knutsen G, Drogset JO, Engebretsen L, Grontvedt T, Isaksen V, Ludvigsen TC, Roberts S, Solheim E, Strand T, Johansen O: A randomized trial comparing autologous chondrocyte implantation with microfracture. Findings at five years. J Bone Joint Surg Am. 2007, 89: 2105-2112. 10.2106/JBJS.G.00003.CrossRefPubMed

19.

Saris DB, Vanlauwe J, Victor J, Haspl M, Bohnsack M, Fortems Y, Vandekerckhove B, Almqvist KF, Claes T, Handelberg F, Lagae K, Bauwhede van der J, Vandenneucker H, Yang KG, Jelic M, Verdonk R, Veulemans N, Bellemans J, Luyten FP: Characterized chondrocyte implantation results in better structural repair when treating symptomatic cartilage defects of the knee in a randomized controlled trial versus microfracture. Am J Sports Med. 2008, 36: 235-246. 10.1177/0363546507311095.CrossRefPubMed

20.

Behrens P, Bitter T, Kurz B, Russlies M: Matrix-associated autologous chondrocyte transplantation/implantation (MACT/MACI) – 5-year follow-up. Knee. 2006, 13: 194-202. 10.1016/j.knee.2006.02.012.CrossRefPubMed

21.

Marcacci M, Berruto M, Brocchetta D, Delcogliano A, Ghinelli D, Gobbi A, Kon E, Pederzini L, Rosa D, Sacchetti GL, Stefani G, Zanasi S: Articular cartilage engineering with Hyalograft C: 3-year clinical results. Clin Orthop Relat Res. 2005, 96-105. 10.1097/01.blo.0000165737.87628.5b. 435

22.

Erggelet C, Sittinger M, Lahm A: The arthroscopic implantation of autologous chondrocytes for the treatment of full-thickness cartilage defects of the knee joint. Arthroscopy. 2003, 19: 108-110.CrossRefPubMed

23.

Drobnic M, Radosavljevic D, Ravnik D, Pavlovcic V, Hribernik M: Comparison of four techniques for the fixation of a collagen scaffold in the human cadaveric knee. Osteoarthritis Cartilage. 2006, 14: 337-344. 10.1016/j.joca.2005.11.007.CrossRefPubMed

24.

Bartlett W, Skinner JA, Gooding CR, Carrington RW, Flanagan AM, Briggs TW, Bentley G: Autologous chondrocyte implantation versus matrix-induced autologous chondrocyte implantation for osteochondral defects of the knee: a prospective, randomised study. J Bone Joint Surg Br. 2005, 87: 640-645. 10.1302/0301-620X.87B5.15905.CrossRefPubMed

25.

Mark von der K, Kirsch T, Nerlich A, Kuss A, Weseloh G, Gluckert K, Stoss H: Type X collagen synthesis in human osteoarthritic cartilage. Indication of chondrocyte hypertrophy. Arthritis Rheum. 1992, 35: 806-811. 10.1002/art.1780350715.CrossRefPubMed

26.

Aigner T, Bertling W, Stoss H, Weseloh G, Mark von der K: Independent expression of fibril-forming collagens I, II, and III in chondrocytes of human osteoarthritic cartilage. J Clin Invest. 1993, 91: 829-837. 10.1172/JCI116303.PubMedCentralCrossRefPubMed

27.

Dehne T, Karlsson C, Ringe J, Lindahl A, Sittinger M: Gene expression profiling of HYAFF-11 cartilage transplants generated by chondrocytes from OA donors [abstract]. Tissue Eng Part A. 2008, 14: 737-

28.

Stevens MM, George JH: Exploring and engineering the cell surface interface. Science. 2005, 310: 1135-1138. 10.1126/science.1106587.CrossRefPubMed

29.

Teo WE, He W, Ramakrishna S: Electrospun scaffold tailored for tissue-specific extracellular matrix. Biotechnol J. 2006, 1: 918-929. 10.1002/biot.200600044.CrossRefPubMed

30.

Sohier J, Moroni L, van Blitterswijk C, de Groot K, Bezemer JM: Critical factors in the design of growth factor releasing scaffolds for cartilage tissue engineering. Expert Opin Drug Deliv. 2008, 5: 543-566. 10.1517/17425247.5.5.543.CrossRefPubMed

31.

Caplan AI: Mesenchymal stem cells. J Orthop Res. 1991, 9: 641-650. 10.1002/jor.1100090504.CrossRefPubMed

32.

Kuo CK, Li WJ, Mauck RL, Tuan RS: Cartilage tissue engineering: its potential and uses. Curr Opin Rheumatol. 2006, 18: 64-73. 10.1097/01.bor.0000198005.88568.df.CrossRefPubMed

33.

Murphy JM, Dixon K, Beck S, Fabian D, Feldman A, Barry F: Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum. 2002, 46: 704-713. 10.1002/art.10118.CrossRefPubMed

34.

Scharstuhl A, Schewe B, Benz K, Gaissmaier C, Buhring HJ, Stoop R: Chondrogenic potential of human adult mesenchymal stem cells is independent of age or osteoarthritis etiology. Stem Cells. 2007, 25: 3244-3251. 10.1634/stemcells.2007-0300.CrossRefPubMed

35.

Kafienah W, Mistry S, Dickinson SC, Sims TJ, Learmonth I, Hollander AP: Three-dimensional cartilage tissue engineering using adult stem cells from osteoarthritis patients. Arthritis Rheum. 2007, 56: 177-187. 10.1002/art.22285.CrossRefPubMed

36.

Eder J, Dehne T, Perka C, Ringe J, Sittinger M: Towards in situ tissue repair of osteoarthritis: differentiation and migration potential of patient-derived mesenchymal stem cells [abstract]. Tissue Eng Part A. 2008, 14: 923-

37.

Murphy JM, Fink DJ, Hunziker EB, Barry FP: Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum. 2003, 48: 3464-3474. 10.1002/art.11365.CrossRefPubMed

38.

Osiris Therapeutics, Inc. homepage. [http://www.osiristx.com]

39.

Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D: Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician. 2008, 11: 343-353.PubMed

40.

Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M: Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage. 2002, 10: 199-206. 10.1053/joca.2001.0504.CrossRefPubMed

41.

Wakitani S, Nawata M, Tensho K, Okabe T, Machida H, Ohgushi H: Repair of articular cartilage defects in the patellofemoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. J Tissue Eng Regen Med. 2007, 1: 74-79. 10.1002/term.8.CrossRefPubMed

42.

Marcacci M, Kon E, Moukhachev V, Lavroukov A, Kutepov S, Quarto R, Mastrogiacomo M, Cancedda R: Stem cells associated with macroporous bioceramics for long bone repair: 6-to 7-year outcome of a pilot clinical study. Tissue Eng. 2007, 13: 947-955. 10.1089/ten.2006.0271.CrossRefPubMed

43.

Tanaka T, Komaki H, Chazono M, Fujii K: Use of a biphasic graft constructed with chondrocytes overlying a beta-tricalcium phosphate block in the treatment of rabbit osteochondral defects. Tissue Eng. 2005, 11: 331-339. 10.1089/ten.2005.11.331.CrossRefPubMed

44.

Ringe J, Häupl T, Sittinger M: Future of tissue engineering in rheumatic diseases. Expert Opin Biol Ther. 2007, 7: 283-287. 10.1517/14712598.7.3.283.CrossRefPubMed

45.

Chamberlain G, Fox J, Ashton B, Middleton J: Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007, 25: 2739-2749. 10.1634/stemcells.2007-0197.CrossRefPubMed

46.

Erggelet C, Neumann K, Endres M, Haberstroh K, Sittinger M, Kaps C: Regeneration of ovine articular cartilage defects by cell-free polymer-based implants. Biomaterials. 2007, 28: 5570-5580. 10.1016/j.biomaterials.2007.09.005.CrossRefPubMed

47.

BioTissue Technologies GmbH homepage. [http://www.biotissue.de]

48.

Ringe J, Strassburg S, Neumann K, Endres M, Notter M, Burmester GR, Kaps C, Sittinger M: Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem. 2007, 101: 135-146. 10.1002/jcb.21172.CrossRefPubMed

49.

Fiedler J, Roderer G, Gunther KP, Brenner RE: BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells. J Cell Biochem. 2002, 87: 305-312. 10.1002/jcb.10309.CrossRefPubMed

50.

Endres M, Neumann K, Häupl T, Erggelet C, Ringe J, Sittinger M, Kaps C: Synovial fluid recruits human mesenchymal progenitors from subchondral spongious bone marrow. J Orthop Res. 2007, 25: 1299-1307. 10.1002/jor.20394.CrossRefPubMed

51.

Dazzi F, van Laar JM, Cope A, Tyndall A: Cell therapy for autoimmune diseases. Arthritis Res Ther. 2007, 9: 206-10.1186/ar2128.PubMedCentralCrossRefPubMed

52.

Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002, 30: 42-48. 10.1016/S0301-472X(01)00769-X.CrossRefPubMed

53.

Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A: Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005, 106: 1755-1761. 10.1182/blood-2005-04-1496.CrossRefPubMed

54.

Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G: Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 2007, 56: 1175-1186. 10.1002/art.22511.CrossRefPubMed

55.

Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE: Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006, 108: 2114-2120. 10.1182/blood-2005-11-011650.PubMedCentralCrossRefPubMed

56.

Sudres M, Norol F, Trenado A, Grégoire S, Charlotte F, Levacher B, Lataillade JJ, Bourin P, Holy X, Vernant JP, Klatzmann D, Cohen JL: Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol. 2006, 176: 7761-7767.CrossRefPubMed

57.

Djouad F, Fritz V, Apparailly F, Louis-Plence P, Bony C, Sany J, Jorgensen C, Noel D: Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum. 2005, 52: 1595-1603. 10.1002/art.21012.CrossRefPubMed

58.

Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O, Developmental Committee of the European Group for Blood and Marrow Transplantation: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008, 371: 1579-1586. 10.1016/S0140-6736(08)60690-X.CrossRefPubMed

59.

Papadaki HA, Marsh JC, Eliopoulos GD: Bone marrow stem cells and stromal cells in autoimmune cytopenias. Leuk Lymphoma. 2002, 43: 753-760. 10.1080/10428190290016854.CrossRefPubMed

60.

Kastrinaki MC, Sidiropoulos P, Roche S, Ringe J, Lehmann S, Kritikos H, Vlahava VM, Delorme B, Eliopoulos GD, Jorgensen C, Charbord P, Häupl T, Boumpas DT, Papadaki HA: Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis. 2008, 67: 741-749. 10.1136/ard.2007.076174.CrossRefPubMed

61.

Del Papa N, Quirici N, Soligo D, Scavullo C, Cortiana M, Borsotti C, Maglione W, Comina DP, Vitali C, Fraticelli P, Gabrielli A, Cortelezzi A, Lambertenghi-Deliliers G: Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum. 2006, 54: 2605-2615. 10.1002/art.22035.CrossRefPubMed

62.

Bocelli-Tyndall C, Bracci L, Spagnoli G, Braccini A, Bouchenaki M, Ceredig R, Pistoia V, Martin I, Tyndall A: Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and autoimmune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford). 2007, 46: 403-408. 10.1093/rheumatology/kel267.CrossRef

63.

Kwan MD, Slater BJ, Wan DC, Longaker MT: Cell-based therapies for skeletal regenerative medicine. Hum Mol Genet. 2008, 17: R93-98. 10.1093/hmg/ddn071.CrossRefPubMed

64.

Fickert S, Fiedler J, Brenner RE: Identification of subpopulations with characteristics of mesenchymal progenitor cells from human osteoarthritic cartilage using triple staining for cell surface markers. Arthritis Res Ther. 2004, 6: R422-432. 10.1186/ar1210.PubMedCentralCrossRefPubMed

65.

Pei M, He F, Vunjak-Novakovic G: Synovium-derived stem cell-based chondrogenesis. Differentiation. 2008, 76: 1044-1056. 10.1111/j.1432-0436.2008.00299.x.PubMedCentralCrossRefPubMed

66.

De Bari C, Dell'Accio F, Luyten FP: Failure of in vitro-differentiated mesenchymal stem cells from the synovial membrane to form ectopic stable cartilage in vivo. Arthritis Rheum. 2004, 50: 142-150. 10.1002/art.11450.CrossRefPubMed

67.

Bielby RC, Boccaccini AR, Polak JM, Buttery LD: In vitro differentiation and in vivo mineralization of osteogenic cells derived from human embryonic stem cells. Tissue Eng. 2004, 10: 1518-1525.CrossRefPubMed

68.

Wakitani S, Aoki H, Harada Y, Sonobe M, Morita Y, Mu Y, Tomita N, Nakamura Y, Takeda S, Watanabe TK, Tanigami A: Embryonic stem cells form articular cartilage, not teratomas, in osteochondral defects of rat joints. Cell Transplant. 2004, 13: 331-336. 10.3727/000000004783983891.CrossRefPubMed

69.

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007, 131: 861-872. 10.1016/j.cell.2007.11.019.CrossRefPubMed

70.

Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA: Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007, 318: 1917-1920. 10.1126/science.1151526.CrossRefPubMed

71.

Zhang Z, McCaffery JM, Spencer RG, Francomano CA: Hyaline cartilage engineered by chondrocytes in pellet culture: histological, immunohistochemical and ultrastructural analysis in comparison with cartilage explants. J Anat. 2004, 205: 229-237. 10.1111/j.0021-8782.2004.00327.x.PubMedCentralCrossRefPubMed

72.

Bonaventure J, Kadhom N, Cohen-Solal L, Ng KH, Bourguignon J, Lasselin C, Freisinger P: Reexpression of cartilage-specific genes by dedifferentiated human articular chondrocytes cultured in alginate beads. Exp Cell Res. 1994, 212: 97-104. 10.1006/excr.1994.1123.CrossRefPubMed

73.

Lemare F, Steimberg N, Le Griel C, Demignot S, Adolphe M: Dedifferentiated chondrocytes cultured in alginate beads: restoration of the differentiated phenotype and of the metabolic responses to interleukin-1beta. J Cell Physiol. 1998, 176: 303-313. 10.1002/(SICI)1097-4652(199808)176:2<303::AID-JCP8>3.0.CO;2-S.CrossRefPubMed

74.

Häupl T, Yahyawi M, Lübke C, Ringe J, Rohrlach T, Burmester GR, Sittinger M, Kaps C: Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007, 12: 328-340. 10.1177/1087057107299261.CrossRefPubMed

75.

Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T: Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford). 2006, 45: 669-675. 10.1093/rheumatology/kel065.CrossRef

76.

Lübke C, Ringe J, Krenn V, Fernahl G, Pelz S, Kreusch-Brinker R, Sittinger M, Paulitschke M: Growth characterization of neo porcine cartilage pellets and their use in an interactive culture model. Osteoarthritis Cartilage. 2005, 13: 478-487. 10.1016/j.joca.2004.01.009.CrossRefPubMed

77.

Lübke C, Andreas K, Yahyawi M, Krenn V, Morawietz L, Ringe J, Burmester GR, Häupl T, Kaps C, Sittinger M: Gene expression profiling of an in vitro tissue model for cartilage destruction [abstract]. Altex. 2006, 23: 113-http://www.altex.ch/resources/AbstractsLinz20064.pdf.

Title: Tissue engineering in the rheumatic diseases
Authors: Jochen Ringe
Michael Sittinger
Publication date: 01-02-2009
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue 1/2009
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar2572

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Hypoxia. HIF-mediated articular chondrocyte function: prospects for cartilage repair

The differential expressions of 78-kDa glucose-regulated protein of infiltrating plasma cells in peripheral joints with the histopathological variants of rheumatoid synovitis

Erratum to: What magnetic resonance imaging has told us about the pathogenesis of rheumatoid arthritis – the first 50 years

Implication of granulocyte-macrophage colony-stimulating factor induced neutrophil gelatinase-associated lipocalin in pathogenesis of rheumatoid arthritis revealed by proteome analysis

Heavy metal exposure reverses genetic resistance to Chlamydia-induced arthritis

Gene therapy of the rheumatic diseases: 1998 to 2008

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials